American School of Oncology

Stage IV Bronchoalveolar Carcinoma: Disease Progression following Second Line Chemotherapy

Release Date: June 2, 2004

Course Overview:

This case module discusses the disease progression of stage IV bronchoalveolar carcinoma following second line chemotherapy. It provides a review of research on various treatment options and concludes with recommendations for treatment and the need for further exploration.

This activity will be valid until June 2, 2005.

Objectives:

At the completion of this course, physicians will be better able to:

Discuss research findings concerning second line chemotherapy treatment in stage IV bronchoalveolar carcinoma.
Describe current recommendations for treatment of stage IV bronchoalveolar carcinoma.

Faculty:

Roy Herbst, MD, PhD
Chief, Section of Thoracic Medical Oncology
MD Anderson Cancer Center
Houston, Texas

According to the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education, the faculty has been asked to disclose significant financial arrangements related to the content of this continuing medical education program. Dr. Herbst participates in formal advisory activities; and specific research activities for Genentech and AstraZeneca. Dr. Herbst is also on the speakers' bureau for Genentech and AstraZeneca, and participates in the development of educational materials for Genentech and AstraZeneca.

Target Audience:

This educational activity has been designed to meet the educational needs of oncologists.

Accreditation Information:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Alabama School of Medicine and the Network for Oncology Communication and Research. The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Alabama School of Medicine designates this educational activity for a maximum of 0.25 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

Time to completion:

It will take 0.25 hours to complete this course.

Commercial Support:

Support for this program has been provided by an unrestricted educational grant from AstraZeneca.

Participation in the course:

This course is offered in a case format online. Successful completion of the course and course evaluation will lead to an online certificate for 0.25 Category 1 credits that can be printed for your records. To receive credit, the course must be completed before June 2, 2005.

Physicians Click Here To Continue

Other Professions Click Here to Continue

The information provider by this service is intended for use as continuing education only. The user assumes full responsibility and all risks for the appropriate use of the information contained or provided by this NOCR service. The opinions of the expert discussant(s) expressed in this service are not necessarily those of the Network for Medical Communications & Research, LLC (NMCR). NMCR makes no warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, product, or process disclosed.